Deals: Page 16
-
Amgen bets almost $4B on a biotech and its inflammation drugs
The deals hands Amgen a few clinical programs and a marketed therapy in Tavneos, which was approved last year to treat a group of autoimmune diseases.
By Jacob Bell • Aug. 4, 2022 -
Courtesy of AbCellera
AbCellera inks another venture partnership, this time with Atlas
One week after striking a deal with Versant, the antibody specialist is teaming up with Atlas to provide drug candidates to an undisclosed startup backed by the biotech investor.
By Delilah Alvarado • Aug. 3, 2022 -
AbbVie, targeting a well-known protein family, expands a partnership into neuroscience
It’s the second deal in as many years between AbbVie and Sosei Heptares, which together have been trying to develop drugs that target so-called G protein-coupled receptors.
By Jacob Bell • Aug. 2, 2022 -
Getty Images
Ipsen, continuing oncology push, pays a startup $45M for two cancer drugs
The French company will work with Marengo Therapeutics in an alliance that could be worth as much as $1.6 billion.
By Delilah Alvarado • Aug. 1, 2022 -
Photo illustration by Maura Sadovi/BioPharma Dive; photograph by Carl Court via Getty Images
US secures updated COVID boosters in $1.7B deal with Moderna
Health officials are gearing up for a fall vaccination campaign and aim to deploy shots modified to better match circulating omicron subvariants.
By Delilah Alvarado • July 29, 2022 -
Permission granted by Sekar Kathiresan
Vertex, Verve team up to develop a gene editing drug for liver disease
The deal, which is worth $60 million upfront, broadens Vertex’s reach into gene editing and expands Verve’s research beyond heart disease.
By Ben Fidler • July 20, 2022 -
Courtesy of AbbVie
AbbVie, building eye-care business, pays $60M for implantable glaucoma treatment
The pharma has secured an option to buy iSTAR Medical, which sells a small implant that helps lower eye pressure and is cleared for use in Europe.
By Elise Reuter • July 20, 2022 -
Getty Images
Nestlé expands microbiome drug work with biotech deal
The food giant will pay French company Enterome about $40 million to join in the development of an inflammatory bowel disease drug as well as other food allergy treatments.
By Delilah Alvarado • July 18, 2022 -
Getty Images
Ultragenyx sells rare disease drug royalties to Canadian pension fund
In exchange for $500 million, the fund, called OMERS, will get a 30% royalty on future sales of Ultragenyx’s drug Crysvita in the U.S. and Canada, where it’s approved to treat two rare conditions.
By Jacob Bell • July 15, 2022 -
Getty Images
Royalty Pharma buys rights to top-selling GSK drug in pair of deals
The prolific biopharma dealmaker is paying Theravance $1.1 billion and Innoviva $282 million to acquire rights to royalties on GSK’s asthma and COPD drug Trelegy Ellipta.
By Kristin Jensen • July 14, 2022 -
Spencer Platt via Getty Images
TherapeuticsMD buyout unravels as shareholders balk
Too few investors in the women’s health company pledged their shares to the take-private offer from EW Healthcare Partners, killing the deal.
By Delilah Alvarado • July 13, 2022 -
Courtesy of Vertex Pharmaceuticals
Vertex acquires another maker of potentially curative diabetes treatments
For $320 million, Vertex said it plans to buy ViaCyte in a deal that would provide “complementary assets, capabilities and technologies” to the ones it picked up through the 2019 acquisition of Semma Therapeutics.
By Jacob Bell • July 11, 2022 -
Getty Images
Healthcare asset manager Innoviva buys another biotech at a bargain price
Two months after acquiring Entasis Therapeutics, the firm reached a deal to buy La Jolla Pharmaceutical Co. at a fraction of what La Jolla was worth just a few years ago.
By Jonathan Gardner • July 11, 2022 -
Carl Court via Getty Images
ADC Therapeutics cuts deal with Sobi to broaden reach of cancer drug
The alliance comes on the heels of a change in leadership at ADC and will help ready the biotech to launch its lymphoma drug in Europe.
By Delilah Alvarado • July 8, 2022 -
National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
AbbVie dials back partnership on experimental Alzheimer's drug
While AbbVie is bailing on one of the two programs it paid Alector $205 million to acquire five years ago, work will continue on the second project. That drug, however, has shown safety signals.
By Jonathan Gardner • July 8, 2022 -
Getty Images
Radius, fending off activists, outlines pitch for $890 million buyout
The biotech detailed the process that led to its take-private offer last month, aiming to win the support of shareholders, including two firms that have pushed for change.
By Ben Fidler • July 8, 2022 -
Elizabeth Regan/BioPharma Dive
After a lengthy drought, could biotech M&A be on the upswing?
With at least 14 buyouts worth $50 million or more, the second quarter was one of the busiest three-month periods for acquisitions in recent years. Some industry watchers expect that pace to continue.
By Jacob Bell • July 8, 2022 -
Carol Highsmith. (2005). "The Apex Building" [Photo]. Retrieved from Wikimedia Commons.
As Merck closes in on Seagen, the FTC nears a key test on pharma deals
An acquisition reportedly worth $40 billion or more and potentially signed within weeks could draw notable scrutiny from regulators and force the companies to divest certain drug programs.
By Jonathan Gardner , Ben Fidler • July 7, 2022 -
Getty Images
Two cancer biotechs merge, raise cash as sector-wide downturn continues
Syros Pharmaceuticals and Tyme Technologies, shares of which trade near all-time lows, will combine and raise about $130 million in the latest example of how the industry’s slump is affecting publicly traded biotechs.
By Delilah Alvarado • July 5, 2022 -
Courtesy of CureVac
CureVac sues rival COVID-19 vaccine maker BioNTech for patent infringement
The biotech, whose own efforts to develop a COVID-19 vaccine have faltered, claims its inventions were crucial to the development of BioNTech’s top-selling coronavirus shot.
By Jonathan Gardner • July 5, 2022 -
Christopher Furlong via Getty Images
With $100M AstraZeneca deal, a biotech and its investors engineer another buyout
An entity originally known as Teneobio has now been the focus of three acquisition deals with large pharmaceutical companies since 2021, capitalizing on the industry’s growing interest in dual-acting antibody drugs.
By Ben Fidler • July 5, 2022 -
Brian Tucker / BioPharma Dive/BioPharma Dive
Blueprint secures access to more than $1B in funding through two new deals
Amid a historic market downturn, the precision drug company is raising money through royalty financings with Sixth Street and Royalty Pharma.
By Jacob Bell • June 30, 2022 -
Getty Images
Bayer, Amgen back ReCode's plan to broaden genetic medicine's reach
The two drugmakers joined a long list of investors, including Pfizer and Sanofi, that have been funding the startup’s plan to develop a new type of lipid nanoparticle technology.
By Delilah Alvarado • June 29, 2022 -
Elizabeth Regan/BioPharma Dive
Ipsen adds to cancer business with bargain buyout of Epizyme
Epizyme, which was once worth more than $2 billion, agreed to be bought for $247 million upfront. The biotech has continued to lose money despite winning FDA approval for a drug for rare cancers.
By Jonathan Gardner • June 27, 2022 -
Radius, maker of bone and cancer drugs, to be bought in take-private deal
Two investment firms, Gurnet Point Capital and Patient Square Capital, have agreed to pay as much as $890 million for Radius, which has come under pressure amid share price declines.
By Ben Fidler, Kristin Jensen • June 23, 2022
Previous
